RxDoctor Payments Data

Thomas Morrison, MD

Cardiovascular Disease · Saint Louis, MONPI 1104021583

Payments from drug & device makers

$1,188in general payments, 2019–2025

Across 44 payments — averaging $27.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$305
  • Edwards Lifesciences$162
  • Novartis$156
  • Abiomed$119
  • Medtronic$95
  • Johnson & Johnson$87
  • plus $265 from 9 others

What the payments were for

  • Food & beverage$1,188100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,188 in reported general payments places this provider in the 35th percentile of 391 cardiovascular disease providers in Missouri.

See all cardiovascular disease providers in Missouri

Medicare billing

Part B allowed, 2024
$195,832
Medicare patients
1,749
Services billed
3,167

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban904$862,316
EntrestoSacubitril/Valsartan277$259,759
JardianceEmpagliflozin90$96,045
XareltoRivaroxaban79$86,044
Repatha SureclickEvolocumab82$69,877
FarxigaDapagliflozin Propanediol34$32,711
MultaqDronedarone Hcl13$24,933
Dabigatran EtexilateDabigatran Etexilate Mesylate39$12,857
Metoprolol Succinate585$8,057
Atorvastatin Calcium688$7,609
Rosuvastatin Calcium441$5,985
Ezetimibe267$5,265
Torsemide274$3,796
Carvedilol339$3,185
Amlodipine Besylate487$2,966

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$45$862,316904 claims
NovartisEntresto$156$259,759277 claims
Johnson & JohnsonXarelto$87$86,04479 claims
Sanofi-aventis U.S. LLCMultaq$20$24,93313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 391 cardiovascular disease providers in Missouri.

Other cardiovascular disease in Saint Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →